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Background: According to previous studies, aortic diameter alone seems to be insufficient to predict the event of
aortic dissection in Marfan syndrome (MFS). Determining the optimal schedule for preventive aortic root
replacement (ARR) aortic growth rate is of importance, as well as family history, however, none of them appear to
be decisive. Thus, the aim of this study was to search for potential predictors of aortic dissection in MFS.
Methods: A Marfan Biobank consisting of 79 MFS patients was established. Thirty-nine MFS patients who
underwent ARR were assigned into three groups based on the indication for surgery (dissection, annuloaortic
ectasia and prophylactic surgery). The prophylactic surgery group was excluded from the study. Transforming
growth factor-β (TGF-β) serum levels were measured by ELISA, relative expression of c-Fos, matrix metalloproteinase
3 and 9 (MMP-3 and −9) were assessed by RT-PCR. Clinical parameters, including anthropometric variables - based
on the original Ghent criteria were also analyzed.
Results: Among patients with aortic dissection, TGF-β serum level was elevated (43.78 ± 6.51 vs. 31.64 ± 4.99 ng/l, p
< 0.0001), MMP-3 was up-regulated (Ln2α = 1.87, p = 0.062) and striae atrophicae were more common (92% vs. 41%
p = 0.027) compared to the annuloaortic ectasia group.
Conclusions: We found three easily measurable parameters (striae atrophicae, TGF-β serum level, MMP-3) that may
help to predict the risk of aortic dissection in MFS. Based on these findings a new classification of MFS, that is
benign or malignant is also proposed, which could be taken into consideration in determining the timing of
prophylactic ARR.
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Marfan syndrome is an autosomal dominantly inherited
genetic disorder affecting the body’s connective tissue.
The prevalence of the syndrome is 1:3000–1:5000 [1].
Among others, it involves the cardiovascular system,
eyes and the skeletal system. Most patients with Marfan
syndrome were shown to have a mutation in the
fibrillin-1 (FBN1) gene [1,2]. The mutation causes de-
creased Large Latent Complex (LLC) sequestering ability
of the FBN1 protein, which in turn, leads to elevated tis-
sue and serum concentrations of Transforming Growth* Correspondence: kalman.benke@gmail.com
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unless otherwise stated.Factor-β (TGF-β). Elevated TGF-β affects the expression
of many proteins in the connective tissue through both
the standard Smad mediated signal transduction, and al-
ternative (non-canonical) pathways including MAP ki-
nases (ERK1/2, JNK1, p38) with AP-1 transcription
factor (c-Fos/c-Jun complex) as a downstream mediator
[3]. High tissue and plasma activity of matrix metallo-
proteinases (MMPs) – especially gelatinases (MMP-2
and 9) and MMP-3 – are prominent [4-6]. These molecu-
lar alterations entail the fragmentation of the connective
tissue fibres, and results in an inelastic and tear-prone
connective tissue. Due to this inelasticity the wall of the
aorta is not able to resist the force arising from blood
pressure, leading to the formation of aortic pathologies
typical to the syndrome [6,7].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in nearly 100 percent of the individuals with Marfan syn-
drome, varying degrees of aortic root dilatation will have
been developed and three quarters of the patients would
have undergone aortic root replacement (ARR), as the
indication criteria for surgery are fulfilled: either in-
creased aortic diameter to critical level, symptomatic
aortic valve insufficiency or Stanford type “A” dissection
[8]. In most of the Marfan cases, aortic dissection pre-
sents an acute life-threatening condition, and is to be
treated by surgery on an emergency basis. Consequently,
prophylactic ARR should be given priority in Marfan
syndrome patients’ care, in order to prevent aortic
dissection.
Optimal timing of these properly planned operations
with less potential of complications, has a decisive im-
portance with regard to life expectancy and quality of
life of Marfan patients [9]. However, cardiac surgical in-
terventions performed unreasonably early (with small
aortic diameters) in young adulthood or childhood may
lead to early and late complications, in certain cases
leading to reoperation or redo surgery [10,11]. Moreover,
in cases with mechanical valve implantation lifelong
anti-coagulation is unavoidable [12]. These factors can
significantly worsen the quality of life of the asymptom-
atic young patients. In addition, numerous studies have
shown that aortic dissection can also develop in individ-
uals with smaller aortic diameters compared to those di-
mensions, which are included in the current surgical
indication criteria [7,13]. These data suggest, that aortic
diameter alone is not an appropriate indicator of aortic
dissection.
To optimize the timing of the preventive surgical inter-
vention, it would be necessary to create a model that
could precisely determine the risk and also the probable
onset of aortic dissection for each individual. Hence, we
established a systematic Marfan Biobank with relatively
large sample collection, in order to gain a better over-
view of pathomechanism and the underlying molecular
pathways of the diverse cardiovascular manifestations.
Based on the Biobank data, we present three possible
extracardiac predictors of aortic dissection in Marfan
syndrome, and we propose a new classification (benign
and malignant form) indicating the probable cardiovas-
cular outcome.
Methods
Patients’ selection was implemented from the Hungarian
Marfan Registry (HMR) set up and maintained by the
staff of the Heart and Vascular Center at Semmelweis
University. Clinical data of 221 Hungarian patients with
Marfan syndrome were collected in the HMR between
1988 and 2011. In each patient enrolled in the HMR,
diagnosis was established according to the originalGhent nosology [14]. However in 2011, when patients
were selected for the current study, the diagnosis was
verified in every case with the use of the revised (2010)
Ghent criteria [15]. The ethical approval was obtained
from the Scientific and Research Ethical Committee of
the Medical Research Council (ETT-TUKEB 13699/
2011).
Ghent criteria
The main components of the original Ghent nosology
were the major and minor criteria representing the de-
gree to which each of the six affected organ systems
were involved. According to this classification three fur-
ther genetic and family history criteria should have been
taken into consideration (the presence of FBN1 muta-
tion causing MFS; a haplotype around the FBN1 gene
which was also present in a diagnosed MFS relative; par-
ent, child or sibling meeting the diagnostic criteria). If
two major criteria in two separate organ systems and the
involvement of a third organ system was present, or the
patient had a FBN1 mutation proven to cause MFS ac-
companied by one major criterion and the involvement
of another organ system the diagnosis of MFS could
have been established in the index case. For relatives of
the index case one major criterion and the involvement
of another organ system was enough for the diagnosis.
The revised Ghent nosology introduces the concept of
the systemic score and outlines seven scenarios for the
diagnosis of MFS based on the different combinations of
cardinal manifestations (aortic involvement, ectopia len-
tis, FBN1 mutation, systemic score) and family history.
(Tables 1 and 2)
Establishment of the Marfan Biobank
63 patients from the HMR were chosen randomly. First
and second degree relatives of these 63 patients, who
were diagnosed with Marfan syndrome and had a record
in HMR, were also assigned to this group (another 16
patients). Thus a total of 79 patients were enrolled in
the Marfan Biobank. Between October 2011 and April
2012 clinical data and biological samples (serum, blood,
genomic DNA, cDNA from PBMC) from 37 women
(47%) and 42 men (53%) with Marfan syndrome were
collected in the biobank. At the time of the establish-
ment of the biobank the patients’ average age was 33.2 ±
13.5 years.
Forty out of the 79 patients underwent cardiac surgery
(primary type of the surgery were ARR in 39 cases and
mitral valve replacement in 1 case). Among the 39 pa-
tients with ARR surgical indication was aortic dissection
in 12 cases (Group 1; no distinction between the 9 acute
and 3 chronic cases was applied in this study), annu-
loaortic ectasia in 12 cases (Group 2) and prophylactic
surgery in 15 cases. Annuloaortic ectasia was defined as
Table 1 Original and revised Ghent nosology
Organ system (involvement) Major Minor
Skeletal The presence of more than 4: moderate pectus excavatum
(2 maj OR 1 maj and 2 min) - pectus carinatum joint hypermobility
- pectus excavatum requiring surgical treatment highly arched palate crowding of teeth
- reduced USLS ratio or ASHR greater than 1.05 Facial abnormalities:
- wrist and thumb signs - dolichocephaly
- scoliosis of more than 20° or spondylolisthesis - malar hypoplasia
- reduced extension of the elbows - enophtalmus
- medial displacement of the medial malleolus, pes planus - retrognathia
- protusio acetabuli of any degree - down-slanting palpebral fissures
Ocular ectopia lentis abnormally flat cornea
(2 min) increased axial length of the eyeball
hypoplastic iris, ciliary muscle, decreased miosis
Cardiovascular ascending aortic dilatation mitral valve prolapse
(1 min OR 1 maj) dissection of the ascending aorta pulmonary arteria dilatation
mitral annulus calcification
type B aortic dissection <50 years
Pulmonary (1 min) spontaneous pneumothorax
apical pulmonary blebs
Skin (1 min) striae atrophicae
Dura (1 maj) Lumbosacral dural ectasia
Original Ghent nosology (maj: major criterion/criteria, min: minor criterion/criteria, ASHR: arm span to height ratio, USLS: upper segment to lower segment ratio).
Table 2 Revised Ghent nosology
P Systemic involvement (>7 point) Diagnostic scenarios
3
OR
Wrist AND thumb sign I Aortic involvement AND Ectopia lentis
1 Wrist OR thumb sign II Aortic involvement AND FBN1 mutation
2
OR
Pectus carinatum III Aortic involvement AND Systemic involvement
1 Pectus excavatum OR chest asymmetry IV Aortic involvement AND Family history
2
OR
Hindfoot deformity V Ectopia lentis AND FBN1 mutation
1 Plain pes planus VI Ectopia lentis AND Family history
2 Pneumothorax VII Systemic involvement AND Family history
2 Dural ectasia
2 Protusio acetabuli
1 USLS↓ AND ASHR↑ AND no scoliosis
1 Scoliosis OR thoracolumbar kyphosis
1 Reduced elbow extension
1 Facial abnormalitis (see above)
1 Striae atrophicae
1 Myopia > 3 diopters
1 Mitral valve prolapse
Revised Ghent nosology (P: systemic score point; ASHR: arm span to height ratio, USLS: upper segment to lower segment ratio, FBN1: fibrillin-1 gene).
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severe, hemodynamically significant (grade III-IV) aortic
insufficiency. In contrast, ARRs performed in patients,
who had an aortic diameter over 40–50 mm – measured
at the level of the sinus of Valsalva – or an aortic growth
rate exceeding 5 mm/year, were classified as prophylactic
surgery, if aortic regurgitation was either mild (grade I-II)
or completely absent. The above range of aortic dia-
meters corresponds to the changes in the recommended
indication criteria for prophylactic ARR in Marfan
syndrome patients published in the past two decades
[13,16,17].
It is also to emphasize, that while aortic dissection and
annuloaortic ectasia are well-defined, distinct manifesta-
tions of Marfan syndrome, patients who underwent
prophylactic surgery could have developed either aortic
dissection or annuloaortic ectasia without the preventive
ARR. Therefore we excluded this mixed, intermediate
population from our investigation.
Sample collection was conducted 6.7 ± 5.1 years after
the surgery. The samples required were collected and
handled according to the international protocol at the
Heart and Vascular Center of Semmelweis University.
The samples were processed in 2 hours following the
collection. Oral mucosa samples were collected from 5
subjects under 14 and their extracted genomic DNA was
stored.
Control group
To avoid variances arising from the patients’ individual
biological features, molecular sampling and measurements
were conducted on control patients as well. Between
October 2010 and December 2011 control biological sam-
ples (serum, blood, genomic DNA, cDNA from PBMC)
from 33 women (41%) and 47 men (59%) were collected.
At the time of sampling, the patients’ average age was
35.4 ± 11.2 years. In control patients’ history, there were
no cardiovascular disease, cancer, immune-mediated dis-
ease, vascular or cardiac surgical intervention.
TGFβ1 ELISA
For the measurement of serum active TGF-β1 levels a solid
phase ELISA was used, which was designed to measure bio-
logically active TGF-β1 (R&D Systems, Minneapolis, USA).
0.25 ml Serum samples were acidified to a pH of 2–3
with 50 μl 1 N HCL for 10 minutes to activate latent
TGF-β, and then re-neutralized to pH 7–8 with 50 μl
1.2 N NaOH/0.5 M HEPES. Results were expressed in
ng/ml.
cDNA synthesis and real-time PCR assay
PBMC was isolated from 5 ml of the anticoagulated
blood samples (containing EDTA) of the 76 adult pa-
tients. Total RNA from PBMC cells content was isolatedwith Quick RNA microprep kit (Zymo Research, Irvine,
USA). RNA concentration was determined using Nano-
Drop spectophotometer (NanoDrop, Wilmington, USA).
Reverse transcription was performed in 20 μl target vol-
ume using 5 μg whole RNS, 75 pmol random hexamer
primer, 10 mM dNTP (Invitrogen, Bedford, USA), 20 U
M-MuLV Reverse Transciptase enzyme (MBI Fermentas,
New York, USA) and 1x-es buffer (MBI Fermentas, New
York, USA). The reaction mix was incubated for 2 hours
at 42°C. The reverse transcriptase reaction solution was
diluted three-fold with nuclease-free water. For the real-
time PCR assay, 1 μl diluted cDNS (approximately 15 ng
RNA-equivalent) and 1 x SYBR Green Master Mixet
(Applied Biosystems, Bedford, USA) were used. Primers
were designed using Primer Express Software (Applied
Biosystems, Bedford, USA). Primer sequences are de-
tailed in Additional file 1: Table S1. Real-time PCR was
performed in 20 μl target volume using 1 μl cDNA, 1
pmol, gene-specific Forward and Reverse primer and 1 x
SYBR Green PCR Master mix. All real-time PCR were
performed using the MX3000 Real-time PCR (Stratagen,
Santa Clara, USA) system with the following settings:
40 cycles at 95°C, denaturing process for 15 seconds, an-
nealing at 60°C, chain elongation and detection for
60 seconds. For each gene, relative expression was nor-
malized using the human GAPDH gene as standard.
ΔCt values were calculated as Ct(target gene) - Ct
(GAPDH endogenous control gene) in the same sample,
while ά value was defined as ΔCt(control sample) - ΔCt
(target sample). This value was used to calculate expres-
sion fold value (Ln 2ά) by the equation. Significantly up-
or down-regulated if the Ln ratio of the ά value is >1
or < −1, respectively, with p < 0.05. The ELISA and real-
time assays were validated.
Clinical variables
In the two specified subgroups we assessed sex ratio,
family history, age, anthropometric parameters, presence
of major and minor criteria in the original Ghent nos-
ology whereas the systemic score was calculated on the
basis of the revised Ghent nosology from 2010 [14,15].
Positive family history was defined as the presence of
at least one first- or second-degree relative with the
diagnosis of Marfan-syndrome. In cases where the above
condition was not met, family history was considered
negative (sporadic cases).
Measurement (height, lower segment - LS, arm span -
AS, weight) and calculation (upper segment - US, upper
segment to lower segment ratio - USLS, arm span to
height ratio - ASHR) of anthropometric values were car-
ried out according to the instructions of Ghent nosology
[14]. Length parameters and weight were expressed in
centimetres and kilograms respectively. Shoe sizes were
assessed in the units of continental European system.
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area (BSA) and the well-known formula for body mass
index (BMI).
Along with the collection of biological samples the
presence of major and minor Ghent criteria – queried
from HMR database – were verified with the use of col-
lected cardiological, ophthalmological, orthopedic and
dermatological evidences and inspection.Statistical methods
In case of continuous parameters with normal distribu-
tion Student’t-test was performed. Non-normally dis-
tributed variables were compared with the use of
Mann–Whitney U test. In case of dichotomous parame-
ters – with regards to the small sample size – two-tailed
Fisher’s exact test was calculated. Multivariate logistic
regression analysis was performed to identify the inde-
pendent predictors of aortic dissection. The internation-
ally accepted probability (p < 0.05) was chosen for
significance level. Data were stored in Microsoft Excel
2010 and analysed with the SPSS statistical program
(version 20.0, Chicago, IL, USA).Results
Molecular biological parameters
TGF-β serum level was significantly higher (see values
below) in both groups established according to the surgi-
cal indication, than in the control group (25.7 ± 4.1 ng/l;
p < 0.0001 for both groups) (Figure 1).
TGF-β level measured in the dissection (43.78 ±
6.51 ng/l) group was significantly higher than that mea-
sured in the annuloaortic ectasia group (31.64 ± 4.99 ng/l;
p < 0.0001).Figure 1 TGF-β serum levels in the aortic dissection, annuloaortic ectThe MMP-3 gene showed significant up-regulation in
dissection patients with Marfan syndrome in comparison
with control patients (Ln2α = 2.22, p = 0.046). There was
no change in the MMP-3 gene expression level of the
annuloaortic ectasia group when compared to the con-
trol group (Ln2α = 0.31, p = 0.089) (Figure 2).
The MMP-3 gene showed up-regulation in dissection
patients when compared to annuloaortic ectasia individ-
uals (Ln2α = 1.87, p = 0.062) (Figure 2).
MMP-9 gene showed significant up-regulation in dissec-
tion patients compared to the control patients (Ln2α =
1.85, p = 0.043). MMP-9 gene showed up-regulation in
annuloaortic ectasia patients compared to the control pa-
tients, however, this change was insignificant (Ln2α = 1.74,
p = 0.069) (Figure 2).
Compared to the annuloaortic ectasia patients there
was no significant difference in the MMP-9 gene expres-
sion level of dissection patients with Marfan syndrome
(Ln2α = 0.11, p = 0.039) (Table 3).
In the expression of the c-FOS gene there was no dif-
ference between the dissection and annuloaortic ectasia
groups compared to the control group (Ln2α = −0.38,
p = 0.096; Ln2α = 0.03, p = 0.081 respectively). Investigat-
ing the subgroups established according to surgical indi-
cation, there was no difference between them in the
c-FOS gene expression (dissection vs. annuloaortic ecta-
sia: Ln2α = −0.34, p = 0.083) (Figure 2), (Table 3).Clinical variables
Our findings from the analysis of clinical parameters are
illustrated in Table 4.
These results highlight the fact, that the presence of
one criteria from the Ghent nostology, namely striae
atrophicae, was significantly more common amongasia and in the control patients expressed in ng/ml.
ab
c
Figure 2 Ln2α values describing the relative expression of the MMP-3 (a), MMP-9 (b) and c-FOS (c) genes. ΔCt is Ct(target gene) - Ct
(GAPDH endogenous control gene) in the same sample, ά value is ΔCt(control sample) - ΔCt(target sample). This value is used to calculate
expression fold value by the equation (expression fold value Ln 2ά). Significantly up- or down-regulated if the Ln ratio of the ά value is >1
or < −1, respectively, with p < 0.05.
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group (92% vs. 41% p = 0.027) (Table 4).
According to the low number of observed Marfan pa-
tients, only TGF-β revealed as an independent risk fac-
tor for aortic dissection (OR 1.609, 95% CI 1.068-2.424,
p = 0.023).Table 3 Gene expression
MMP-3 MMP-9
Compared groups α value ± SE (α) Ln 2α p α value
C vs 1 3.21 ± 0.95 (α1) 2.22 0.046* 2.68 ± 0.
C vs 2 0.46 ± 1.02 (α2) 0.31 0.089 2.52 ± 1.
2 vs 1 2.7 ± 0.91 (α3) 1.87 0.062 0.16 ± 0.
*significant data, α1 = ΔCtC– ΔCt1, α2 = ΔCtC – ΔCt2, α3 = ΔCt2 – ΔCt1; 1: Aortic disDiscussion
The key issue in the treatment of patients with Marfan
syndrome is the prevention of life-threatening aortic dis-
section for which - according to the current state of
knowledge - the only solution seems to be ARR. The in-
creasing risk of acute aortic dissection caused byc-FOS
± SE (α) Ln 2α p α value ± SE (α) Ln 2α p
84 (α1) 1.85 0.043* −0.56 ± 1.03 (α1) −0.38 0.096
03 (α2) 1.74 0.069 0.05 ± 0.99 (α2) 0.03 0.081
52 (α3) 0.11 0.039* −0.5 ± 0.62 (α3) −0.34 0.083
section group; 2: Annuloaortic ectasia group; C: Control group.
Table 4 Clinical data
Aortic dissection Annuloaortic ectasia p
Patients 12 12
Anthropometric (measured)
Height 178.5 ± 10.30 186.2 ± 11.74 0.106
Lower segment (cm) 93.58 ± 9.45 101.9 ± 10.95 0.058
Arm span (cm) 186.92 ± 13.78 189.6 ± 15.2 0.656
Foot size 42.2 ± 2.5 44.0 ± 3.1 0.148
Weight (kg) 74.9 ± 14.7 75.0 ± 17.0 0.989
Anthropometric (calculated)
Upper segment (cm) 85.0 ± 7.8 84.2 ± 9.9 0.839
Body Mass Index (BMI; kg/m2) 23.4 ± 3.70 21.45 ± 3.62 0.204
Body surface area (m2) 1.92 ± 0.22 1.961 ± 0.27 0.686
Upper segment - Lower segment ratio (USLS) 0.918 ± 0.132 0.838 ± 0.147 0.176
Arm span - Height ratio (ASHR) 1.046 ± 0.042 1.018 ± 0.039 0.092
TGF-β serum level (ng/l) 43.78 ± 6.51 31.64 ± 4.99 <0.0001*
Ghent nosology (%)
Mitral valve prolapse 58% 75% 0.667
Pectus carinatum 33% 67% 0.220
Pectus excavatum requiring surgery 17% 8% 1.000
Reduced upper to lower segment ratio 33% 50% 0.680
Increased arm span to height ratio 58% 17% 0.089
Wrist sign 83% 83% 1.000
Thumb sign 83% 83% 1.000
Scoliosis of > 20° or spondylolisthesis 83% 58% 0.370
Severe scoliosis 58% 42% 0.684
Reduced extension at the elbows 17% 8% 1.000
Medial displacement of the medial malleolus causing pes planus 33% 33% 1.000
Heel deformity 8% 17% 1.000
Pectus excavatum of moderate severity 25% 33% 1.000
Asymetric chest 33% 33% 1.000
Joint hypermobility 75% 42% 0.213
Highly arched palate with crowding of teeth 58% 42% 0.684
Facial appearance 50% 16% 0.400
Dolichocephaly 25% 17% 1.000
Enophtalmos 8% 8% 1.000
Retrognathia 42% 8% 0.155
Ectopia lentis 25% 17% 1.000
Myopia over 3 diopter 8% 17% 1.000
Increased axial length of globe 0% 8% 1.000
Spontaneous pneumothorax 8% 8% 1.000
Striae atrophicae (stretch marks) 92% 42% 0.027*
Positive family history (%) 50% 50% 1.000
Sex (male) 4 9 0.099
Systemic score 7 [5-8] 7 [5.5-8] 0.860
*significant data.
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by preventive cardiac surgery, performed at small aortic
diameters at the early stages of the disease [18,19]. Fur-
thermore, the short and long-term survival rates for pa-
tients having undergone prophylactic surgery, as well as
the rates of complications and subsequent reoperations
are far more favourable than for those, who have ARR
procedures in an emergency situation [9,17]. In the past
two decades ARR surgery tends to be performed at
smaller and smaller aortic diameter (in 1991 at >6 cm
[16]; in 1994 at >5.5 cm [17]; in 2005 at >4.5 cm [13];
nowadays certain experts recommend it at even >3 cm
[16]). Thus, because of the progressive nature of aortic
dilatation, patients are much younger nowadays when
surgical intervention is performed.
However, ARR performed in a young patient – as any
surgical treatment – may have considerable risks. After
ARR procedure, several life-threatening complications
may occur even among patients having no cardiac symp-
toms prior to the operation [10-12].
It has also been pointed out that in case of Marfan
syndrome, aortic dissection may occur at smaller aortic
diameters, even smaller than those, quoted in the latest
surgical indication criteria [7,13]. Thus, considering lit-
erature data presented above, aortic diameter, alone does
not seem to be sufficient and satisfactory to predict the
formation of aortic dissection.
New classification: benign and malignant form
In order to rule out certain limitations, several attempts
have been made. To exclude the strong variations in
body size typical to Marfan syndrome patients, Aalberts
et al. specified aortic diameters normalized to body sur-
face area and patient age, instead of using the absolute
value [20]. In addition, patients’ family history of aortic
dissection as well as aortic growth rate is taken into ac-
count by most of the protocols [20,21]. Nevertheless, be-
sides these factors, identification of other clinical and
molecular markers would be necessary, to predict the
trends describing the progression and direction of the
aortic pathology.
Being aware of the prognostic parameters (both clinical
and molecular biological) of aortic dissection, preventive
surgical intervention – which usually exposes Marfan syn-
drome patients to considerable risks and potential compli-
cations – should only be carried out, if there is a real
danger of aortic dissection. Optimal timing for ARR pro-
cedure could be also calculated more precisely, which
would further improve the life expectancy and quality of
life of patients with Marfan syndrome.
As Meijboom et al. showed in their research, the growth
rate of aortic dilatation is quite variable among Marfan
syndrome patients [13]. At early stages, when aortic
growth rate is slow (“slow grower”) the disease isasymptomatic. However, during the decades, patients
develop annuloaortic ectasia, which leads to aortic valve
insufficiency. In this case, the risk of dissection is lower.
In contrast, rapid growth of the aortic root (“fast
grower”) can be characterized by an increased risk of
aortic dissection.
Based on the data above, patients with Marfan syn-
drome should be assigned into two groups: malignant
(with an increased risk of dissection) and benign (with
a reduced risk of dissection). However, instead of the
growth rate alone as Meijboom et al. suggested, we
hypothesize that the main difference between the two
groups lies in the presence or absence of certain, yet
unmapped, pathological alterations at molecular bio-
logical and connecting tissue level, which can cause
aortic dissection even in case of aortic diameters
close to normal [7,13]. We also assume that these
molecular alterations, if present in a patient, can also
influence the pattern of the extracardiac manifesta-
tions of the syndrome.
Molecular and extracardiac phenotypic characteristics of
the hypothetical malignant group
It is known that the tissue and serum levels of TGF-β,
which increase the expression of several proteolytic en-
zymes, are elevated in patients with Marfan syndrome
[6,22]. However, our results suggest, that molecular alter-
ation of this kind is more pronounced in dissection pa-
tients. The highly significant difference in the TGF-β
serum level between the dissection and annuloaortic ecta-
sia groups indicates, that increased TGF-β levels may not
only play an important role in the development of the
symptoms, but also the degree of the increase in the
serum levels may correlate with the risk of dissection.
Furthermore, increased MMP-3 expression in the
PBMC cells of the patients with dissection compared to
the annuloaortic ectasia group, apparently contributes to
the development of the severe pathologic changes lead-
ing to aortic dissection. Since in terms of c-FOS expres-
sion no distinction could be identified between these
two groups, it seems unlikely that the detrimental effects
of increased TGF-β level are resulting from the activa-
tion of the ERK1/2, JNK1, p38 mediated non-canonical
pathways and the consequent up-regulation of the AP-1
transcription factor (AP-1 is a heterodimer of c-Fos and
other proteins). Thus, it is more likely that Smad medi-
ated canonical or Rho-like GTPase and PI3K/Akt medi-
ated non-canonical pathways are responsible for the
signal transduction causing the up-regulation of MMP-3
and destruction of the aortic wall [4].
Results from an earlier study show that MMP-3 is also
responsible for the activation of latent TGF-β; therefore,
at this central point of the signaling pathway a positive
feedback cycle should be considered [6,23] (Figure 3).
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7.1 ± 5.1 years after the event of aortic dissection, thus it
can be ruled out that the above mentioned molecular al-
terations (elevated TGF-β levels, up-regulated MMP-3)
is caused by the dissection itself.
Our findings also indicate that certain groups of pa-
tients with Marfan syndrome can be characterized by
yet unidentified phenotypic correlations. The develop-
ment of aortic dissection is significantly more often
associated with atrophic striae compared to annu-
loaortic ectasia.
There are limited data available on the molecular
mechanisms causing atrophic striae. Although, based on
previous publications and on our gene expression re-
sults, we assume that the increased MMP-3 and MMP-9
activity in dissection patients is responsible for acceler-
ated degradation of the connective tissue fibres [4,5,24].
Besides the aortic wall, this destruction process may
affect the dermis and the subcutaneous layer of the
skin as well. Therefore MMP-3 and MMP-9 can beFigure 3 This figure depicts a hypothetical positive feedback cycle in
picture fibrillin-1 mutation leads to elevated serum and tissue Transforming
latent TGF-β decreases. Through intracellular signal transduction active TGF
Increased MMP activity in the connective tissue in turn leads to the integri
of the active TGF-β tissue level. Both aortic dissection and striae (stretch m
This positive feedback cycle could provide a link between aortic dissection
expression and striae atrophicae) described in this article.considered as common mediators in the pathogenesis of
both aortic dissection and atrophic striae (Figure 3).
In summary, increased presence of atrophic striae
along with the above mentioned two molecular markers
(elevated TGF-β levels and MMP-3 up-regulation) may
be important characteristics of the hypothetical malig-
nant group.
Conclusions
Based on our findings we conclude that our hypothetical
(dignity) groups (benign vs. malignant) are distinct not
only from the cardiovascular perspective, but also in terms
of phenotypic signs related to other organs (striae), which
can be caused by molecular alterations, demonstrated
above (TGF-β, MMP-3). Thus, a total of three – two mo-
lecular and one clinical – factors which might predict aor-
tic dissection were found: elevated TGF-β serum level (1),
increased expression of MMP-3 gene in peripheral blood
mononuclear cells (2), and the presence of striae atrophi-
cae (3). Differences in the extracardiac clinical parametersthe homeostasis of connective tissue fibres. As shown in the
Growth Factor-β levels, as the ability of fibrillin-1 protein to sequester
-β up-regulates matrix metalloproteinases (MMP-3 and MMP-9).
n dependent activation of latent TGF-β which results in further increase
arks) may be the consequence of increased tissue activity of MMPs.
and the three extracardiac predictors (TGF-β serum level, MMP-3
Ágg et al. BMC Cardiovascular Disorders 2014, 14:47 Page 10 of 11
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molecular factors could be assessed by relatively inexpen-
sive laboratory tests (ELISA, RT-PCR).
Similar phenotypic features of the skin - which may
predict the cardiovascular pathologies - have not been
described in the international literature of Marfan syn-
drome so far. Likewise, there are also few studies in
which the connection between phenotypic differences is
analysed [25].
Limitations, future objectives
Our current findings are not sufficient to define how
many of these three predictive factors are necessary to
assign a Marfan syndrome patient to the benign or the
malignant group; neither can we specify the optimal tim-
ing of prophylactic ARR procedure in the malignant or
benign group.
In order to prove our hypothesis regarding to the classi-
fication of patients with Marfan syndrome into benign
and malignant groups, we consider it necessary to repeat
the examinations involving a larger number of patients, as
well as to carry out further serum level measurements,
genetic and gene expression tests. Investigation of mo-
lecular pathways underlying certain phenotypic relation-
ships would provide further evidence for the existence of
the above mentioned benign-malignant groups and would
support their characterization.
According to the low number of observed Marfan pa-
tients, only TGF-β revealed as an independent risk fac-
tor for aortic dissection. However this study was a pilot
study, further examination and the increase of the pa-
tient population would be necessary for correct risk
scores, which would help to choose the optimal timing
of the prophylactic ARR procedure.
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